A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, DOSE-RANGING STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF INTRAVENOUS TAK-954 IN CRITICALLY ILL PATIENTS WITH ENTERAL FEEDING INTOLERANCE
- Registry ID
- TAK-954-2002
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- MILLENNIUM PHARMACEUTICALS INC
- Start date
- 2018-08-21
- Last update
- 2018-04-06
Conditions
- ENTERAL FEEDING INTOLERANCE
View on source registry